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Abstract
Increased brain α-synuclein (SNCA) protein expression resulting from gene duplication and 
triplication can cause a familial form of Parkinson’s disease (PD). Dopaminergic neurons exhibit 
elevated iron levels that can accelerate toxic SNCA fibril formation. Examinations of human post 
mortem brain have shown that while mRNA levels for SNCA in PD have been shown to be either 
unchanged or decreased with respect to healthy controls, higher levels of insoluble protein occurs 
during PD progression. We show evidence that SNCA can be regulated via the 5′untranslated 
region (5′UTR) of its transcript, which we modeled to fold into a unique RNA stem loop with a 
CAGUGN apical loop similar to that encoded in the canonical iron-responsive element (IRE) of L- 
and H-ferritin mRNAs. The SNCA IRE-like stem loop spans the two exons that encode its 5′UTR, 
whereas, by contrast, the H-ferritin 5′UTR is encoded by a single first exon. We screened a library 
of 720 natural products (NPs) for their capacity to inhibit SNCA 5′UTR driven luciferase 
expression. This screen identified several classes of NPs, including the plant cardiac glycosides, 
mycophenolic acid (an immunosuppressant and Fe chelator), and, additionally, posiphen was 
identified to repress SNCA 5′UTR conferred translation. Western blotting confirmed that 
Posiphen and the cardiac glycoside, strophanthidine, selectively blocked SNCA expression (~1 
μM IC50) in neural cells. For Posiphen this inhibition was accelerated in the presence of iron, thus 
providing a known APP-directed lead with potential for use as a SNCA blocker for PD therapy. 
These are candidate drugs with the potential to limit toxic SNCA expression in the brains of PD 
patients and animal models in vivo.
Summary
We describe ten clinically relevant compounds, including the AD experimental drugs Posiphen and 
(−)-phenserine, that we have identified to exhibit specific targeting to the SNCA 5′UTR. In each 
case, declines in SNCA production in cells lines were achieved at concentrations that are within 
the clinical realm, and support the future in vivo analysis of these candidates in appropriate rodent 
models to vigorously define their translational capacity to therapeutically impact SNCA in vivo 
without toxicity.
Keywords
Parkinson’s disease; Alpha-synuclein; 5′untranslated region; Transfection-based screen; Natural 
product; Translation blockers; Amyloid precursor protein; Posiphen; Phenserine
Introduction
α-Synuclein (SNCA) is a 104-amino-acid-long protein implicated in the pathogenesis of 
Parkinson’s disease (PD) among other alpha-synculeinopathies, such as dementia with Lewy 
bodies (DLB) and multiple system atrophy (MSA) in humans (Ueda et al. 1993). Gene 
dosage was demonstrated in the etiology of these diseases, as duplication and triplication 
can cause inheritable forms of PD and DLB in rare families (Singleton et al. 2003). In 
addition, conformational changes (Lashuel et al. 2002) and oligomerization are also 
hypothesized to underlie alpha-synucleinopathies, as known point mutations have been 
shown to accelerate aggregation in vitro to strongly increase the presence of the beta specific 
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fibril-forming conformer that is toxic to dopaminergic neurons and other brain cells 
(Uversky 2007), in some cases by iron-associated pathways (Ostrerova-Golts et al. 2000). In 
these rare cases of familial PD several reports have thus far identified three sets of culprit 
point mutations such as A53T, A30P and E46K (Cabin et al. 2005). These and other rare 
kindreds express altered or over-expressed SNCA that can cause a toxic gain of function and 
dopaminergic neural death.
Pathologically, SNCA-related disorders are characterized by the deposition of SNCA 
aggregates, Lewy Bodies and dystrophic neuritis (Kruger et al. 2000; Baba et al. 1998; 
Braak et al. 2003, 2006; Forno 1996; Irizarry et al. 1998). In contrast, MSA is characterized 
by the presence of glial cytoplasmic inclusions (Banati et al. 1998; Campbell et al. 2001).
SNCA is a highly preserved protein (Uversky 2007) normally found in presynaptic terminals 
(Goedert 2001). In Homo Sapiens there are three confirmed isoforms with the SNCA-140 
being the most abundant (Uversky 2007) (Fig. 1). Most of the known mutations of SNCA 
accumulate at the N-terminus, which also harbors four imperfect repeats (KTKGV). Amino 
acids 61–96 constitute the so-called non-amyloid component (NAC) of the protein. This 
region predisposes SNCA to aggregation (Uversky 2007). The C-terminus harbors three of 
the four tyrosine residues present in SNCA. Truncations of the C-terminus promote 
aggregation (Li et al. 2005). SNCA is a disordered protein with no structure that can quickly 
respond to changes in its environment (Uversky 2007). As a natively unfolded protein, 
SNCA is very sensitive to its environment, and it can undergo a number of conformational 
switches in response to changes in environmental conditions (Uversky et al. 2001a). The 
unfolded protein is normally found under physiological conditions in vivo and in vitro. A 
pre-molten globular state can be induced by changes in temperature and pH or after 
exposure to pesticides (Uversky et al. 2001b). Shifts from a random coil to alpha-helical 
structures are observed when SNCA is exposed to lipids and lipidic membranes (Perrin et al. 
2000). Shifts in temperature, presence of pro-oxidative conditions (Norris et al. 2003; Souza 
et al. 2000) and transition metals and divalent cations can promote the formation of dimers 
and other polymeric forms of SNCA (Conway et al. 1998; Lowe et al. 2004; Yamin et al. 
2003). Eventually, SNCA can form large, insoluble aggregates with two predominant 
morphologies: fibrillar and amorphous aggregates (Uversky et al. 2002).
Events associated with the inflammatory cascade, iron metabolism and translational control 
of gene expression have been associated with PD and Lewy body dementia (DLB). 
Disrupted signaling events such as occur in response to inflammatory cytokines, for example 
mutations to the signaling kinase LRRK-2, may activate inflammatory events in this 
neurodegenerative disease (Cahill and Rogers 2008; Taylor et al. 2006). Novel signaling 
pathways may additionally be relevant (Cahill et al. 2009). Certainly, increased iron in the 
individual dopaminergic neurons of the substantia nigra has been shown to be closely 
associated with the pathogenesis of PD (Oakley et al. 2007). DLB brains exhibit lowered 
SNCA mRNA but have higher amounts of insoluble protein (Fig. 1), suggesting mis-
regulation of SNCA mRNA translation in addition to its clearance by chaperones (Cantuti-
Castelvetri et al. 2005). In this regard, translational control of SNCA is governed, at least in 
part, by a uniquely configured iron-responsive element (IRE) in the 5′UTR of SNCA 
mRNA as discussed below (see Cahill et al. (2009) for the relevance of iron in PD).
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Iron-responsive element-dependent translational control of iron homeostasis: links to 
neurodegenerative disease genes
IREs are RNA stem loops that were first described in the untranslated regions (UTRs) of 
ferritin and transferrin-receptor mRNAs that are critical to iron homeostasis through their 
modulated interaction with the RNA binding proteins, iron-regulatory proteins (IRP) 1 and 2 
(Rogers et al. 2008). In general, IRP2 has been reported to predominate over IRP1 when 
controlling IRE-dependent regulation of the iron homeostatic pathways for ferritin 
translation and transferrin receptor mRNA stability (Cho et al. 2010; Wang et al. 2007). 
However, the IRE stem loop encoded by the 5′UTR of the mRNAs for hypoxia inducible 
factor 2 alpha (Hif-2a) (Zimmer et al. 2008), ferroportin (IREG-1) (McKie et al. 2000), the 
erythroid heme biosynthetic aminolevulinate synthase (eALAS) (Wingert et al. 2005) and 
mitochondrial aconitase (Goforth et al. 2010) each bind more avidly to IRP1 than IRP2. 
Interestingly, the duodenal divalent metal ion transporter (DMT1) encodes a 3′UTR specific 
IRE stem loop immediately downstream from its stop codon and preferentially binds IRP1 
to mediate iron-dependent message stability, an event that may be critical for setting rates of 
dietary iron uptake (Gunshin et al. 2001).
The Alzheimer-disease-specific amyloid precursor protein (APP) is up-regulated by iron 
influx, and it encodes a 5′UTR specific and fully functional IRE RNA stem loop (Cho et al. 
2010; Rogers 2002; Rogers et al. 2008). Similar to Hif-2α (Zimmer et al. 2008), IRP1 
predominates to control expression of the copper/zinc metalloprotein APP at the level of 
message translation (Cho et al. 2010). APP also appears to regulate iron homeostasis itself. 
Recently, APP, like astrocytic bound brain ceruloplasmin, was shown to be a potent 
ferroxidase via an active iron binding REXXE domain (Rogers 2002) and may thus 
represent a cofactor with ferroportin to export iron from neurons (Duce et al. 2010) and 
across brain sub-compartments. In such a scenario, ferroportin may represent a key 
transporter of iron that has been assimilated across the brain endothelial lining cells. At this 
stage, the closely bound APP may, for example, directly load incoming iron into brain 
transferrin (made by oligodendrocytes) in addition to facilitating excess by iron export from 
neurons, in each case for safe storage of iron.
Similar to APP, SNCA appears to have a role in iron metabolism/homeostasis since this 
protein has been shown to track with heme biosynthetic genes in its expression profile and is 
at its highest abundance in developing reticulocytes (Scherzer et al. 2008). Consistent with 
this finding, this report supports presence of the putative IRE encoded by the 5′UTR of the 
SNCA transcript (Cahill et al. 2009; Friedlich et al. 2007; Olivares et al. 2009) and 
demonstrates that FDA approved drugs, including iron chelator mycophenolic acid, can 
impact to limit SNCA 5′UTR directed translation in neural cell lines and also repress SNCA 
levels in an iron-dependent manner. These RNA-directed SNCA inhibitors represent a novel 
neuro-protective strategy for PD.
RNA targeting as a therapeutic strategy to control neurodegenerative diseases
RNA-directed drugs have long been used in the treatment of infectious diseases, as 
epitomized by antibiotic macrolides and aminoglycosides (Porse et al. 1999). These drugs 
are capable of controlling reporter gene expression in cell culture models (Thomas and 
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Hergenrother 2008; Werstuck and Green 1998). More recently, RNA-directed therapeutic 
strategies were employed to control viral gene expression (Hepatitis C) (Malina et al. 2005), 
HIV (Hamy et al. 1997) and ferritin gene expression (protection from Fe catalyzed oxidative 
stress) (Tibodeau et al. 2006). For example, the H-ferritin 5′UTR was successfully 
modulated with an IRE-specific RNA-targeting drug, yohimbine, to increase ferritin 
translation (Tibodeau et al. 2006).
The role of the APP 5′UTR has been well characterized, which encouraged us to undertake 
the present study of the SNCA gene (Cahill et al. 2009). Notably, the presence of a ‘CAGA 
box’ within the 5′UTR mRNA of the APP gene unique to amyloid plaque forming species 
and absent in all APLP-1/2 genes has prompted us to utilize this unique region as a potential 
drug target (Cho et al. 2010; Maloney et al. 2004; Lahiri et al. 2005; Shaw et al. 2001). The 
functional characterization of the APP 5′UTR and its role in cytokine-mediated APP gene 
expression has obvious implications in Alzheimer’s disease (Lahiri et al. 2003), which led to 
the proposed concept of a “UTRosome” (Lahiri et al. 2005; Rogers et al. 2008) as the seat of 
the gene’s post-transcriptional control, the major focus of the present work.
In the case of endogenous neurodegenerative disease genes, we have applied RNA 
therapeutic strategies to identify drugs that limit the translation of the Alzheimer’s APP 
mRNA (Rogers 2002). This system provides an excellent precedent for the use of 5′UTR 
targeting strategies towards other major neurodegenerative diseases, in particular 
Parkinson’s disease since our alignments revealed a 50% sequences similarity between the 
APP and SNCA 5′UTRs (Cahill et al. 2009; Friedlich et al. 2007). Based on this, we 
predicted that there would be overlap in the spectrum of drugs that suppress APP mRNA 
translation through its 5′UTR with those that suppress SNCA translation. In this regard, we 
have previously demonstrated that the Alzheimer’s disease anticholinesterase (−)-phenserine 
(Greig et al. 1995, 2005; Winblad et al. 2010) lowers APP translation via its 5′UTR and, 
thereby, reduces APP generation in neuronal cell cultures and the brains of animals in vivo 
(Shaw et al. 2001; Venti et al. 2004; Lahiri et al. 2007a, b). This action is not cholinergically 
mediated as it is shared by its (+) enantiomeric form, in the experimental Alzheimer’s 
disease drug, Posiphen. A recent phase 1 clinical trial in subjects with mild cognitive 
impairment demonstrated that Posiphen safely lowers APP levels in the cerebrospinal fluid 
and plasma of humans (Maccecchini et al. 2009; Maccecchini 2010). Thus, Posiphen 
represents a current example of a safe inhibitor of APP translation that can thereby reduce 
the level of peptides derived from APP processing, such as amyloid-b peptide (Shaw et al. 
2001; Lahiri et al. 2007a, b) and other potential toxic N- and C-terminal APP fragments 
(Maccecchini 2010). It hence provides a lead compound to assess actions to lower SNCA 
translation.
Success with APP 5′UTR directed translation blockers prompted our current 
characterization of the SNCA 5′UTR and its usefulness as a drug target for identifying 
SNCA translation blockers. In this report, we describe a screen of a library of natural 
products (NPs) to which we added Posiphen and (−)-phenserine as likely leads to impact 
SNCA translational regulation based on our prior studies. We identified ten specific 
inhibitors of SNCA translation, including several glycosides, and determined that the cardiac 
glycoside, strophanthidine, together with Posiphen/(−)-phenserine demonstrated similar high 
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potencies to block SNCA translation and thereby lower its expression in two distinct 
neuroblastoma cell lines.
Materials and methods
Bioinformatics
RNA sequences from the SNCA gene were located using the NCBI Gene search and the 
Ensembl database. Since the 5′UTRs were of primary interest, the coding regions were 
disregarded, apart from the initiating AUG. Thus, in order to study a balanced sequence, 25 
nucleotides before the splice junction from the first exon were used to create 50 nucleotide 
RNA query sequences (mouse and rat had 52 nucleotide sequences due to insertions).
RNA sequences were aligned using the ClustalX2 graphical program to find evolutionary 
conservation between species. The AUG start region of the CDS was then used as a 
reference point to align the sequences, allowing a comparison of the sequences in both exons 
centered around the splice junction. Secondary structure folding of these RNA sequences 
was generated by the RNAFold webserver at the University of Vienna and was annotated 
using the RNAFold software package utilities. The RNAFold server provided the most 
probable RNA secondary structure for SNCA 5′UTR sequences based on minimum free 
energy calculations (Zuker 1989).
The alignment homology was calculated by comparing a species RNA sequence against the 
H. sapiens sequence on each side of the splice junction. Only nucleotides that matched 
respective to the H. sapiens sequence were scored, and the percent homology was calculated 
by taking the score out of the total nucleotide positions on that side. The two results were 
then compared to better understand the difference in conservation on each side of the splice 
junction.
Transfection-based screen of SNCA 5′UTR specific inhibitors
A library of 720 NPs (Microsource Discovery Systems Inc., Gaylordsville, CT, USA) was 
screened at a concentration of 2 μM in triplicate for inhibition of luciferase expression using 
(APP 5′UTR-Luc cells) and (SNCA-Luc cells). A compound was scored as a hit if all 
replicates gave >65% inhibition in this assay, and as contradictory if at least one, but not all 
replicates gave >65% inhibition.
In order to rule out compounds that reduced luciferase expression due to toxicity, the entire 
library was also screened in both cell lines for cell viability, using the Alamar blue assay 
(Invitrogen, Carlsbad, CA, USA) as the readout. Percent inhibition in the Alamar blue assay 
was calculated and compared with percent inhibition of luciferase activity. Compounds for 
which the difference was greater than 40%, and that scored as a hit in the APP 5′UTR-
luciferase counter-screen luciferase assay, were further evaluated in a dose–response assay.
Luciferase assay
Cells were plated at 2,000 cells/well (APP) or 4,000 cells/well (SNCA) in a 384-well white 
flat-bottom plate (Greiner) in a volume of 50 μl of media. Following overnight incubation, 
50 nl of 2 mM compounds in DMSO was added using a VPN Pintool. Cells were returned to 
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the incubator for 48 h and were then assayed for luciferase activity as follows. Plates were 
allowed to equilibrate to room temperature. After addition of 25 μl Steady-Glo reagent 
(Promega, San Luis Obispo, CA, USA), plates were vortexed for 30 s, and 35 min later 
luminescence was read on an Infinite F2000 plate reader (Tecan, Durham, NC, USA).
Western blot assay
Human H4 neuroglioblastoma and SH-SY5Y and SKNSH neuroblastoma cells were 
cultured in Dulbecco,s modified essential medium (Invitrogen) supplemented with 10% FBS 
(Invitrogen) and penicillin/streptomycin (Bio-Whittaker, Walkerville, MD, USA). Cells were 
exposed to strophanthidine or gitoxigenin at the concentrations indicated and subjected to 
Western blot analysis as described for Posiphen (legend to Fig. 4b). Cells were exposed to 
concentrations of Posiphen, as indicated, in the presence and absence of 50 μM iron and 
ferric ammonium citrate (0, 0.1, 1, 5, 10 micromolar) for 48 h. Cytoplasmic protein lysates 
were prepared by homogenizing the cells in midRIPA buffer (25 mM Tris pH 7.4, 1% NP40, 
0.5% sodium deoxycholate, 15 mM NaCl, protease inhibitors, RNase inhibitor and 10 mM 
DTT). Western blotting for SNCA was performed using mouse monoclonal anti-SNCA (BD 
Transduction Laboratories, Lexington, KY, USA), and anti-β-actin (Chemicon, Rosemont, 
IL, USA). The blots were developed using chemiluminescence (Pierce, Rockford, IL, USA), 
visualized with a PhosphoImager (BioRad, Hercules, CA, USA), and the bands were 
quantified using QuantityOne software (BioRad).
Results
The SNCA 5′UTR is encoded by two exons, as illustrated in Fig. 1a. We bioinformatically 
determined the evolutionary conservation of the SNCA 5′UTR across these two exons. 
Utilizing the SNCA 5′UTR sequence as a drug target, we then performed a screen of 720 
NPs together with Posiphen and (−)-phenserine to identify translation blockers. From the 
identified lead compounds, we then evaluated the potency of three lead glycosides and 
mycophenolic acid as bonafide SNCA translation blockers by use of dose-responsive 
luciferase assays and Western blotting measurements. Finally, we evaluated the iron-
dependent mode of action of Posiphen as a known APP 5′UTR directed translation blocker 
that reduced SNCA levels in SH-SY5Y cells.
Evolutionary characterization of a putative IRE RNA stem loop centered on the single 
splice junction in the human SNCA mRNA 5′UTR
Using human, chimpanzee, bovine, mouse, rat, dog and chicken 5′UTR sequences deposited 
in the NCBI database, we confirmed the presence of the exon-1/exon-2 splice junction 
located 25–28 nucleotides upstream of the start AUG, not only in human and non-human 
primates, but also in other mammals such as mice (Mus musculus), rats (Rattus norvegicus) 
cattle (Bovus taurus) and dog (Canis lupus familiaris) (marked in red highlights in Fig. 2b). 
In humans and chimpanzee, the splice site was found to be 25 bases upstream of the AUG; 
in rats the splice site is 26 bases upstream of the AUG (single uridine insertion) whereas in 
mice the SNCA specific AG/UG splice junction is 28 residues upstream of the start codon 
(5′AUU3′ insertion).
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The layout of the 5′UTR of the H. sapiens SNCA transcript was previously reviewed 
(Olivares et al. 2009). In Fig. 2a of this report the basic features of the SNCA 5′UTR are 
highlighted, most notably the IRE-specific CAGUGN motif resides at the apex of a 
predicted hairpin loop, which is also the splice junction within this UTR. In summary, the 
SNCA mRNA has two exons in the 5′UTR and the splice junction interestingly lies in the 
very center of the CAGUGN motif. Thus, the splice junctions were key criteria used in 
evaluating homology between SNCA RNA in different species, as shown in Fig. 2b.
The alignment of the SNCA sequence of these species was conducted with the ClustalX2 
program, and we observed and highlighted a clear difference in evolutionary conservation 
between exon-1 and exon-2 around the splice junction (see the homology Table in Fig. 2c). 
Across the vertebrate species shown, the sequence of the SNCA exon-2 is much more 
conserved than the sequence in exon-1 preceding the splice junction.
The primates (H. sapiens and Pan troglodytes) showed complete conservation within the 
entire SNCA 5′UTR sequence of the selected RNA regions (100% homology for both exon 
1 and exon 2). Bos taurus and Canis lupus familiaris also showed high level (~96 and 92%, 
respectively) of conservation skewed towards exon 2, compared with a limited (46 and 42%) 
homology within the human exon 1 sequences (see the homology Table in Fig. 2). However, 
M. musculus and R. norvegicus each demonstrated stronger evolutionary divergence from H. 
sapiens in the overall sequence, such that exon 2 retained greater homology (i.e., 65% 
homology between exon 2 of the mouse and human SNCA 5′UTRs but only 42% homology 
between exon 1 for the human and mouse SNCA 5′UTRs). Both species had two nucleotide 
insertions and extended similarities in the exon-2 sequence (expected due to the related 
nature of the two species). Gallus gallus was found to be the most distantly related to H. 
sapiens, with least conservation at the splice junction site and in exon-2, as tabulated in Fig. 
2c.
The 5′UTRs of the SNCA transcript in humans and in non-human primates were predicted 
to fold into RNA stem loops with an apex sequence that is related to the canonical ferritin L- 
and H-chain IREs (Fig. 2d). This incorporates an apical CAGUGN motif (Fig. 2d). Indeed, 
the prediction for the secondary structure of the SNCA 5′UTR has been refined to 
demonstrate a RNA stem loop that can fold to the same AGU psuedotriloop observed at the 
apex of the H-ferritin IREs (Goforth et al. 2010). This is related to a recently reported AGA 
tri-loop that we showed was significant for iron-dependent binding of IRP1 to APP IRE 
sequences as a means to control APP expression (Cho et al. 2010). In sum, L- and H-Ferritin 
IREs encode an AGU triloop sequence at the apex of their hairpin loops, similar to the RNA 
structure of the 5′UTRs of human and chimpanzee SNCA transcripts (Fig. 2d). We observed 
that the central “AGU” motifs from mouse, bovine and canine SNCA mRNA sources were 
predicted to be within the stem, not apex of their 5′UTR specific RNA stem loops. This 
motif was a CGU tri-nucleotide in the case of the rat and chicken genes.
One of the key features of the SNCA 5′UTR was the splice junction that overlapped with 
the CAGUGN motif that is trypical of IREs (Xia et al. 2001). In contrast, the γ- and β-
homologs of SNCA encoded dissimilar 5′UTRs as shown in Fig. 2e. First, β-synuclein has 
two splice junctions in its 5′UTR, at 9 nucleotides and 166 nucleotides from the AUG. 
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Second, the entire 5′UTR of γ-synuclein is encoded by a single exon; the first splice 
junction actually appears 122 nucleotides into the coding sequence. This lack of homology 
is consistent with our rationale for the use of the uniquely folded SNCA IRE as a drug 
target. Any specific inhibitor would be preferred to not reduce β- and γ-synuclein levels and, 
thereby, allow them to maintain their compensatory genetic function.
SNCA translation blockers screened from a library of natural products
To identify SNCA 5′UTR directed translation blockers of SNCA expression in H4 
neuroblastoma cells, we employed a transfection-based screen similar to that used to identify 
several APP 5′UTR directed modulators (Bandyopadhyay et al. 2006b) (Fig. 3). 
Specifically, derived from our library screen, Table 1 summarizes the best ten candidate 
drugs identified as SNCA mRNA translation blockers. Compounds were screened in 
triplicate for inhibition of luciferase expression using SNCA 5UTR cells as the primary 
screening target, and APP 5′UTR cells were employed in the parallel counter-screen. A 
compound was scored as a hit if all replicates gave >65% inhibition in this assay, and as 
contradictory if at least one, but not all replicates gave >65% inhibition. The cutoff for 
specificity was less than 20% inhibitory effect on APP 5′UTR directed translation.
Interestingly, one hit was the drug, harmine, which is already in use for the treatment of PD. 
It induced a 60% inhibition of SNCA translation coupled with low toxicity (10%). Harmine 
is a reversible inhibitor of monoamine oxidase and is a fluorescent harmala analog. Kinetine 
riboside inhibited SNCA translation by 45% and proved not to be toxic (less than 10%). It 
has been reported to possess anticancer activity in a number of human, mouse and plant 
tumor cell lines (Griffaut et al. 2004) and had only a modest inhibitory effect of APP 
translation (10%).
We conducted dose response experiments with four SNCA 5′UTR inhibitors: the 
glycosides, sarmentogenin, strophanthidine and gitoxigenin acetate and the 
immunosuppressant mycophenolic acid (Fig. 4a). The three gylcosides all significantly 
reduced SNCA 5′UTR activity (IC50 ~0.08 μM), and mycophenolic acid exhibited similar 
inhibition, although this declined at higher concentrations. In a concurrent Alamar blue 
assay to assess drug-induced toxicity, mycophenolic acid proved 25% more toxic to H4 cells 
than the three glycosides (n = 3), as was the case in SH-SY5Y cells (not shown).
To define whether translation inhibition determined in the luciferase assay translated to 
lowered protein expression, specific compounds were screened by Western blot analyses. 
Strophanthidine proved to be one of the three glycosidic SNCA 5′UTR directed translation 
blockers that likewise reduced SNCA protein expression (Fig. 4b). In SK-N-SH cells, 
strophanthidine almost completely repressed SNCA expression at 1.6 μM, and possessed an 
IC50 of 0.8 μM. In SH-SY5Y cells SNCA levels were reduced substantially but to a lesser 
extent, approaching 50% at 1.6 μM strophanithidine. We observed no change to the steady-
state levels of either ferritin or β-actin in these experiments (n = 4). Hence, by this criterion, 
strophanthidine proved to be a selective SNCA translation blocker in two distinct 
neuroblastoma cells lines (Fig. 4b). To illustrate the importance of the secondary Western 
blot screen, another SNCA 5′UTR inhibitor lead, gitoxigenin, did not alter SNCA protein 
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expression in either SK-N-SH or SH-SY5Y cells, in which 0.8 and 1.6 mM gitoxigenin was 
without affect (Fig. 4b).
Posiphen inhibition of neural SNCA expression is accelerated by cellular iron
Based on the 50% sequence similarity between the APP and SNCA 5′UTRs (Fig. 2), we 
predicted that drugs that would suppress APP mRNA translation via its 5′UTR may usefully 
impact SNCA mRNA translation, and utilized the Alzheimer experimental drugs Posiphen 
and (−)-phenserine to explore this. Both agents demonstrated activity in the primary screen 
to lower SNCA translation in the luciferase H4 cell screen and, likewise, lowered SNCA 
expression in SK-N-SH cells (not shown). Interestingly and as illustrated with Posiphen in 
Fig. 5, not only was SNCA expression in SH-SY5Y neural cells suppressed, but the potency 
with which this occurred increased in the presence of iron, which is known to be elevated in 
PD brain (Olivares et al. 2009). In this representative experiment, Posiphen inhibited SNCA 
with the same potency as (−)-phenserine IC50 > 5 μM (not shown); however, in the presence 
of iron, Posiphen lowered SNCA expression with an IC50 < 1 μM (Fig. 5).
Discussion
Protein–RNA interactions have been successfully targeted by small drug-like molecules. As 
a recent example, the natural alkaloid yohimbine increased the endogenous expression of 
iron storage protein ferritin by 40% in a cell-free expression system (rabbit reticulocyte 
lysate) by activating the IRE RNA stem loop in the 5′UTR of its transcript (Tibodeau et al. 
2006). Such RNA protein types of interactions are critically important to support the 
continuous endogenous regulation of protein levels in cells to allow them to maintain and 
optimize their function with changes in activity and environment. Pharmacological 
interventions in this process have been sought to prevent viral infections (Howe et al. 2004). 
We recently provided proof-of-concept that it is possible to reduce APP mRNA translation 
and in vivo amyloidosis through the use of FDA pre-approved translation blockers that target 
the APP 5′UTR (Payton et al. 2003; Tucker et al. 2006; Rogers et al. 2002a, b) as well as by 
the experimental Alzheimer drugs, Posiphen and (−)-phenserine (Shaw et al. 2001; Venti et 
al. 2004; Lahiri et al. 2007a, b).
Given the direct association between SNCA and PD, we sought to discover novel drugs to 
reduce SNCA translation by targeting its 5′UTR stem-loop. If successful, this approach 
would provide small molecule probes to elucidate the mechanism of SNCA translation as 
well as provide a new therapeutic strategy for treating PD. To achieve this goal, we initially 
defined conserved sequence elements within the SNCA 5′UTR in order to predict secondary 
RNA structures that may control SNCA translation expression and improve understanding of 
the RNA alignment and folding patterns of this therapeutic RNA target.
The homology percentages listed in Fig. 2c underpin a strong contrast in the pattern of 
evolutionary conservation between exon-1 and exon-2 of non-coding sequences in the 
SNCA genes. The conservation between H. sapiens and P. troglodytes is 100% for both 
exons, as would be predicted from the close evolutionary relationship between these two 
primates. However, the percent homology of exon-1 across all species was found to be 
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significantly lower than that observed for exon-2. This suggests that non-coding sequences 
in exon-2 are significantly more evolutionarily conserved across species than exon-1.
Conspicuously, the 5′UTR of the SNCA transcript folds into a unique RNA stem loop that 
resembles an IRE RNA structure that is related to (but distinct from) the H-ferritin and APP 
5′UTR specific IREs (Cho et al. 2010; Bandyopadhyay et al. 2006a; Rogers 2002). As Fig. 
2e shows, the SNCA IRE is formed at the splice junction of the first two exons in the SNCA 
gene (Olivares et al. 2009). By contrast, the H-ferritin and APP IREs are transcribed from 
the single first exon of their genes, confirming the uniqueness of SNCA translational 
repression via its 5′UTR. Interestingly, the predicted RNA stem loop in the SNCA 5′UTR is 
not found in β- and γ-synuclein mRNAs, as is apparent in Fig. 2e. In this scenario, SNCA 
5′UTR inhibitors would be predicted to leave β- and γ-synuclein unchanged, and such an 
action could prove of value for a proposed drug as these proteins appear to compensate for 
diminished or absent SNCA expression in vivo (Dauer et al. 2002). Although we 
characterized (−)-phenserine and Posiphen as SNCA 5′UTR directed leads, based on their 
known ability to lower translation of APP through related 5′UTR sequences (Shaw et al. 
2001; Lahiri et al. 2007a, b; Utsuki et al. 2007), we nevertheless co-screened for actions on 
APP translation to further define selectivity. From a clinical perspective, however, 
compounds that lack significant differential action between SNCA and APP could retain 
great value, as there remains significant overlap between PD and Alzheimer’s disease 
beyond DLB (Strobel 2009).
From our transfection-based initial screen of a luciferase reporter gene expression when 
driven by the full length 5′UTR of SNCA mRNA in a neural cell line, the major drug class 
of SNCA 5′UTR inhibitors deriving from our 720 NP library proved to be plant glycosides. 
Although these drugs are well known as effective in the treatment of congestive heart failure 
and primarily act to inhibit Na+/K+-ATPase, an enzyme located in the cell membrane that 
promotes the outward transport of Na+ and the inward transport of K+, they were unexpected 
lead anti-SNCA inhibitors. The most potent inhibitors of Na+/K+-ATPase are cardenolides 
and include digoxin, digitoxin, digitoxigenin and strophathidine.
We reproducibly found that strophanthidine’s action as a SNCA 5′UTR inhibitor carried 
through to dopaminergic SK-N-SH and SH-SY5Y cells, where SNCA expression was 
reduced without toxicity (that occurred at 10 μM or greater) (Fig. 4). Others have reported 
an alternative indication in which cardiac glycosides can provide neuroprotection against 
ischemic stroke in a brain slice-based compound screening platform (Wang et al. 2006). 
Strophanthidine derives from the seeds of Strophanthus kombé that has, likewise been 
reported to impact Na/K-ATPase activity and to increase the tone, excitability and 
contractility of cardiac muscles (Wang et al. 2006). In contrast, the actions of the 
cardenolide, gitoxigenin, which is a close analog of strophanthidine and was similarly 
identified as a lead SNCA 5′UTR directed translation blocker from our transfection based 
screen, did not translate to the key secondary assay focused on quantitative changes in 
SNCA expression by Western blot. Whether this relates to a difference between the cell lines 
used in the primary (H4 cells) and secondary (SK-N-SH and SH-SY5Y cells) assays or to 
the different position of hydroxyl groups present on the rings that differentiates the two 
glycosides, remains to be determined. It is clearly apparent that a hierarchy of supporting 
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primary and secondary assays is essential for effective screening of agents prior to 
assessment in animal models of PD. Also evident is that SNCA lowering activity is not a 
property shared by all cardiac glycosides but this activity, nevertheless, provides insight into 
potential mechanisms underpinning SNCA activity. Digoxin and related cardiac glycosides 
repress HIF-1alpha synthesis and block tumor growth (Zhang et al. 2008). Such inhibition of 
Hif-1-alpha is an iron-related activity and provides a means for its inhibition of the IRE-
dependent pathways of gene expression (i.e., suppression of the SNCA IRE activity) (Toth et 
al. 1999). Indeed, IREs are responsive to hypoxic induction of Hif-1-alpha dependent 
activation of IRP1-dependent gene expression (Li et al. 2006).
A structurally unrelated SNCA 5′UTR directed translation blocker proved to be 
mycophenolic acid, an immunosuppressant drug that has been widely used to prevent 
rejection of organ transplantation, in particular renal transplant rejection (Villarroel et al. 
2009). In addition to being an immunosuppressant, mycophenolic acid possesses iron 
chelator activity, thus potentially explaining the mechanism via which it may have generated 
activity against the IRE encoded by the SNCA 5′UTR sequences (Mudge et al. 2004).
Unlike strophanthidine, mycophenolic acid’s concentration-dependent action on luciferase 
activity followed an inverted U-shaped curve. Nevertheless, it represents an interesting lead 
agent that warrants further study.
Similarly, the structurally unrelated compounds Posiphen and (−)-phenserine effectively and 
reproducibly lowered SNCA translation as well as expression across assays and neural cell 
types. Both agents possess the classic hexahydropyrroloindole backbone, present in the 
natural alkaloid physostigmine, but Posiphen exists in the unnatural (+) enantiomeric form 
that lacks anticholinesterase action (Greig et al. 1995, 2005). Posiphen and phenserine, both 
readily enter the brain with a brain/plasma ratio of 7:1 (Greig et al. 2000, 2005). However, 
due to its cholinomimetic effects phenserine cannot be dosed high enough in vivo to achieve 
APP inhibition, whereas Posiphen has been shown to effectively lower APP as well as Aβ 
levels in the brains of a number of rodent models (Lahiri et al. 2007b; Marutle et al. 2007). 
Posiphen, therefore, represents an interesting compound to translate into animal models of 
PD involving elevated SNCA levels. The translation of Posiphen, in particular, into animal 
models is additionally supported by the recent demonstration of the ability of Posiphen (60 
mg QID) to safely lower plasma and CSF levels of APP in a phase 1 clinical trial of subjects 
with mild cognitive impairment and achieve target concentrations commensurate with those 
described herein to lower SNCA expression (Maccecchini et al. 2009; Maccecchini 2010).
In summary, several recent reports have shown SNCA duplication to be a genetic cause of 
familial early onset PD, implicating simple SNCA dose as one of the causative factors in 
disease progression in the striatal neurons of PD patients (Nishioka et al. 2006). A reduction 
in SNCA expression hence represents a rational approach to slow disease progression. In 
this regard, brain infusion of SiRNA by canula and related approaches have successfully 
limited SNCA production in vivo in rodents (Lewis 2009). Our identification of compounds 
that suppress SNCA expression, described in Table 1, may provide a less invasive approach 
to potentially achieve the same goal if target efficacy concentrations can be safely achieved. 
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As several of the agents are in clinic, they are amenable to rapid translation into animal 
models and, if effective, to human PD clinical trials.
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Fig. 1. 
a alpha-synuclein (SNCA) sequence and domains. From left to right: the N terminus 
includes four imperfect repeats (blue boxes) 11-amino-acid long, and harbors three familial 
mutations associated with familial PD (red lines); the central portion is the non-Aβ 
(amyloidogenic) component of SNCA (NAC), this region is involved in alpha-synuclein 
aggregation, the C-terminal domain, the most unstructured part of the protein harbors three 
of the four tyrosines present in the sequence of alpha-synuclein. b Cortical neuron from a 
DLB patient stained for alpha-synuclein shows two prominent inclusions known as Lewy 
bodies (arrows). Lewy bodies can be associated with neuronal loss in the midbrain and other 
subortical nuclei in PD, while in DLB, Lewy bodies are present also in cortical regions
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Fig. 2. 
An RNA stem loop is predicted within the 5′untranslated region (5′UTR) of the Parkinson’s 
disease alpha-synuclein (SNCA) transcript that is homologous to the iron-responsive 
element (IRE) in H-ferritin mRNA. a The SNCA 5′UTR is encoded by exon-1 and exon-2 
of the SNCA gene, which can be alternatively spliced to generate either a shorter exon-1/−2 
transcript (Xia et al. 2001). b Evolutionary alignment of the SNCA 5′UTR relative to the 
human sequence and the CAGUGN loop/splice site sequences (Friedlich et al. 2007). c 
Quantified homology across the SNCA splice junction. d A SNCA 5′UTR stem loop was 
predicted by the RNA/FOLD computer program (ΔG = 53 kcal/mol). This SNCA stem loop 
resembles the classical IRE RNA stem loop (5′CAGUGN3′ loop motif) that controls iron-
dependent L- and H-ferritin translation and transferrin receptor (TfR) mRNA stability. Stem 
loops from the 5′UTRs of several species were predicted to be folded, as described in the 
materials and methods section, and the pseudotriloop AGU is depicted in red lettering at the 
apex of the H-ferritin IRE (Goforth et al. 2010) where the analogous AGA from the APP 
IRE is depicted (Cho et al. 2010). The human SNCA exhibited an AGU triloop whereas in 
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lower vertebrates AGU was located in the stem regions of these transcripts. e Arrangement 
of splice sites and 5′UTR structures in the SNCA, SNCB, SNCG mRNA
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Fig. 3. 
Dicistronic construct designed to screen small molecule inhibitors of SNCA translation: Left 
panel the unique RNA stem-loop target in the 5′UTR of the transcript for SNCA (RNA 
predicted by MULTIFOLD (Cahill and Rogers 2008; Friedlich et al. 2007; Olivares et al. 
2009; Zuker 1989). Right panel transfection-based screen with our dicistronic 
pIRES(SNCA) construct to identify SNCA 5′UTR directed inhibitors of luciferase reporter 
translation, but which selectively maintain GFP translation from the downstream IRES RNA 
structure. This RNA targeting technology has already identified translation inhibitors of APP 
mRNA (as a precedent for AD therapy (Rogers et al. 2002b; Bandyopadhyay et al. 2006b). 
Chemical structures of HTS inhibitors of the APP 5′UTR can be downloaded from 
PUBCHEM at the NCBI website as AID: 1285; we are now also screening for SNCA 
5′UTR directed translation blockers (Broad Inst. Cambridge, MA, USA)
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Fig. 4. 
Strophanthidine as the confirmed top SNCA translation blocker in three separate neural cell 
lines. a H4 cells stably transfected with the H4–2a construct in which SNCA 5′UTR drives 
the translation of a luciferase reporter gene. These cells were treated at incrementally 
increasing concentrations of the SNCA 5′UTR inhibitor hits (0, 0.08, 0.16, 0.31, 0.63, 1.25, 
2.5, 5, 10 μM), and were monitored for luciferase activity and cell viability by Alamar blue 
staining (48 h). All leads exerted no inhibition when counter-screened in control cell lines 
expressing the “empty” luciferase vector pGL3.Conclusion: Of 17 hit SNCA 5′UTR 
directed NP translation inhibitors*, four NPs, the cardiac glycosides strophanthidine, 
digoxigenin, sarmentogenin plus mycophenolic-acetate, exhibited IC50s at <5 μM in dose–
response (without toxicity at initial SNCA inhibitory concentrations). b Western blots 
confirmed strophanthidine reduced SNCA expression in SK-N-SN/SH-SY5Y cells (see 
middle band, IC50 <1 μM). Confirming specificity to SNCA, strophanthidine maintained β-
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actin and H-ferritin levels (IRE encoding mRNA). In contrast, the gitoxigenin hit exerted 
only a minor inhibition of SNCA levels
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Fig. 5. 
Posiphen decreased SNCA levels dose-dependently in dopaminergic SH-SY5Y cells, as was 
reported for APP: The 5′UTRs of both APP and SNCA share 50% homology with the IRE 
H-ferritin mRNA (Friedlich et al. 2007). SH-SY5Y cells were treated with concentrations 
ranging from 0 to 10 μM phenserine and Posiphen for 48 h. Harvested cell lysates were 
prepared [see (Bandyopadhyay et al. 2006a)]. Quantitative Western blotting established the 
anti-SNCA efficacy of Posiphen and phenserine (IC-50 < 5 M); after standardization for β-
actin [Densitometry of multiple lanes (n = 8) by ImageQuant]. Cell viability was unaffected 
[measured by standardized ATP levels/cell (Tm, Cell-Titer-glo™, Promega, Inc.)]
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